Research and Markets: Forecast Insight on Antihypertensives - Fixed-dose Combinations Fail to Offset Generic Erosion

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/d4162d/forecast_insight) has announced the addition of the "Forecast Insight: Antihypertensives - Fixed-dose combinations fail to offset generic erosion" report to their offering.

In 2009, TNF inhibitors were the dominant drug class in terms of sales. However, there is growing use of non-TNF biologics at earlier lines of treatment, and this trend will continue over the next decade. With the first Phase III data from tasocitinib (CP-690,550; Pfizer) reaffirming efficacy with no new safety signals, novel oral small molecules could revolutionize the treatment of RA. Gain insight into the RA market potential utilizing robust 10-year IMS- and patient-based forecasts, enabling commercial opportunity assessment; assess the future competitive landscape, with in-depth profiles of the leading marketed biologics; evaluate future patient numbers and brand dynamics by line of therapy.

Enhance understanding of future product potential, with key opinion leader views of late stage agents in the pipeline, such as tasocitinib and FosD. New product launches, brand reformulations and further biologic uptake will grow the RA market to over $13bn in 2019. Using a patient-based approach, Datamonitor speculates that the RA market for biologics will double from 2009 to reach over 1million patients in 2019, translating to a value that could surpass $15bn.

Datamonitor anticipates non-TNF biologics will be used more frequently at earlier lines of therapy. Bristol-Myers Squibb and Roche, which market Orencia (abatacept) and Actemra (tocilizumab), respectively, are attempting to change the game, with subcutaneous formulations and head-to-head studies against Humira (adalimumab; Abbott, Eisai). Tasocitinib (CP-690,550; Pfizer) demonstrated efficacy with no new safety signals in its first set of Phase III data. Despite ongoing debate over annual cost and positioning, rheumatologists believe tasocitinib has the potential to be a paradigm changing drug, and will achieve blockbuster status in the forecast period, reaching $1.3bn by 2019.

What is the anticipated uptake of Cimzia (certolizumab) and Simponi (golimumab) and can these displace sales of the entrenched TNF brands?

How will first-, second-, third- and fourth-line and above biologic brand dynamics change in the RA market across the 10-year forecast period?

What is the potential market impact from Pfizers tasocitinib, how will it be priced and how will rheumatologists position the novel small molecule?

What impact will subcutaneous Orencia and Actemra have, and will these formulations help to propel non-TNFs further up the treatment algorithm?

Who were the top company players in the rheumatoid arthritis market in 2009 and how will the landscape change to 2019?

Key Topics Covered:

Executive Summary

  • Strategic scoping and focus
  • Datamonitor insight into the disease market
  • Related reports

OVERVIEW

  • Catalyst
  • Summary

MARKET DEFINITION AND OVERVIEW

  • Market definition for this report
  • Countries and regions included in this report
  • Seven major market assessment Rest of world snapshot

BRAND DYNAMICS

  • Overview of competitive landscape
  • Angiotensin-II receptor blockers (ARBs)
  • Direct renin inhibitors
  • Noteworthy pipeline agents

BIBLIOGRAPHY

APPENDIX A MARKET ASSUMPTIONS

APPENDIX B

For more information visit http://www.researchandmarkets.com/research/d4162d/forecast_insight.

Source: Datamonitor



CONTACT:

Research and Markets
Laura Wood, Senior Manager
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Cardiology  Clinical Trials  Pharmaceutical  Professional Services  Other Professional Services

MEDIA:

Logo
 Logo

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.